PROJECT

Projects

Environmental & Social Review Summary

Project Number

48756

Company Name

Joincare Pharmaceutical Group Industry Co., Ltd.

Date ESRS Disclosed

Nov 19, 2024

Country

China

Region

East Asia and the Pacific

Last Updated Date

Nov 20, 2024

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Dec 19, 2023
Signed : Jan 29, 2024
Invested : Jul 11, 2024

Sector

other

Industry

other

Department

Regional Industry - MAS Asia & Pac

Project Description

Founded in 1992, Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare” or the “Company”) is a major manufacturer of gastroenterology, anti-biotics, respiratory and psychiatry chemical drugs, active pharmaceutical ingredients (API) and pharmaceutical intermediates, health supplements, amongst other pharmaceutical products. Headquartered in Shenzhen, China, the Company is listed on the Shanghai Stock Exchange (SHA 600380) with directly operated manufacturing and research & development (R&D) facilities across China. The Company sells its products in China as well as to overseas markets.

 IFC is considering an A Loan of up to US$100 million, to support the Company in  the following areas (together the “Project”) as part of the Company’s expansion plan: (1) production of pharmaceutical APIs at a greenfield facility in Jiaozuo, Henan province, China (Location coordinates: 35.254208, 113.343942); (2) production of finished-formulation respiratory and anti-viral-infection drugs at a greenfield facility to be constructed in Zhuhai Aviation Industrial Park, Guangdong province, China (Location coordinates: 22.054585, 113.318865), and (3) working capital and other capital needs, related to key therapeutic areas. The Jiaozuo and Zhuhai greenfield facilities are both currently at early pre-detailed-design stage.

Overview of IFC's Scope of Review

The scope of IFC’s environmental and social (E&S) review of this investment included assessing Joincare’s systems and capacity to oversee and monitor and manage operational compliance with IFC’s Performance Standards (PS); the World Bank Group (WBG) Environmental Health & Safety (EHS) EHS General Guidelines and WBG EHS Guidelines for Pharmaceutical and Biotechnology Manufacturing (2007); and national E&S regulatory requirements. IFC’s appraisal relied on: (1) reviewing documents and data from the Company and public domain information such as: feasibility study and environmental impact assessment report and regulatory EIA approval documents for the operating Pingshan Shenzhen facility; the company’s corporate policies and procedures on environmental, health, and safety (EHS) and Human Resources (HR) management; EHS training records; EHS monitoring and audit reports, etc; (2) IFC site visits in mid-October 2023 to existing Joincare production facilities at Pingshan and Nanshan in Shenzhen, Guangdong province, China. During site visits, in-depth interviews were conducted with the Company’s senior management including the heads of EHS at headquarter and facility levels, occupational health and safety (OHS), HR, facility and equipment maintenance departments and their team members, as well as with operational staff at various functional areas of visited facilities.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan